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Abstract
Objectives: Monitoring tacrolimus blood concentrations 
is important for preventing allograft rejection in trans-
plant patients. Our hospital offers dried blood spot (DBS) 
sampling, giving patients the opportunity to sample a 
drop of blood from a fingerprick at home, which can be 
sent to the laboratory by mail. In this study, both a volu-
metric absorptive microsampling (VAMS) device and DBS 
sampling were compared to venous whole blood (WB) 
sampling.
Methods: A total of 130  matched fingerprick VAMS, fin-
gerprick DBS and venous WB samples were obtained from 
107 different kidney transplant patients by trained phle-
botomists for method comparison using Passing-Bablok 
regression. Bias was assessed using Bland-Altman. A 
multidisciplinary team pre-defined an acceptance limit 
requiring >80% of all matched samples within 15% of the 
mean of both samples. Sampling quality was evaluated 
for both VAMS and DBS samples.
Results: 32.3% of the VAMS samples and 6.2% of the 
DBS samples were of insufficient quality, leading to 
88  matched samples fit for analysis. Passing-Bablok 
regression showed a significant difference between VAMS 
and WB, with a slope of 0.88 (95% CI 0.81–0.97) but not for 
DBS (slope 1.00; 95% CI 0.95–1.04). Both VAMS (after cor-
rection for the slope) and DBS showed no significant bias 
in Bland-Altman analysis. For VAMS and DBS, the accept-
ance limit was met for 83.0% and 96.6% of the samples, 
respectively.
Conclusions: VAMS sampling can replace WB sampling 
for tacrolimus trough concentration monitoring, but 
VAMS sampling is currently inferior to DBS sampling, 
both regarding sample quality and agreement with WB 
tacrolimus concentrations.
Keywords: dried blood spots; immunosuppressants; 
microsampling; therapeutic drug monitoring; volumetric 
absorptive microsampling.
Introduction
Therapeutic drug monitoring (TDM) of immunosuppres-
sant drugs has been part of routine transplant patient 
care for decades. Sub-therapeutic dosing of immunosup-
pressants, such as tacrolimus, can lead to rejection of the 
allograft, while overdosing can lead to toxicity and side-
effects [1]. Because of great inter- and intra-individual 
variation in pharmacokinetics (PK), dosing of these drugs 
is tailored for each patient based on the blood drug con-
centration. This results in frequent patient visits to the 
hospital for venous blood sampling.
In the past years, several dried blood spot (DBS) 
microsampling methods for tacrolimus have been intro-
duced, enabling patient home sampling [2–11]. Through a 
fingerprick, capillary blood is directly applied to special 
filter paper. After drying, the sample can be sent to the lab-
oratory by mail. This decreases patient burden and allows 
more flexible immunosuppressant monitoring [8, 12]. 
Several of these DBS methods have shown to yield inter-
changeable results with venous whole blood (WB) and 
are routinely applied in transplant patient care, including 
in our hospital [2, 3, 11, 13]. A drawback of DBS applica-
tion is that sampling by the patient does not always lead 
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to sufficient quality DBS samples, and rates of up to 20% 
invalid samples for patient home sampled DBS have been 
reported [11, 14–16].
Volumetric absorptive microsampling (VAMS) was 
introduced as a potential successor of DBS sampling [17]. 
VAMS tips are designed to have several advantages com-
pared to DBS. They wick-up an exact amount of sample 
volume (e.g. 20 μL) into a porous substrate, independ-
ent of hematocrit, and potentially improve the ease of 
sampling for the patient [17–19]. Although the effects of 
the hematocrit on the sample volume can be overcome 
by VAMS, this does not necessarily apply for the effect 
of hematocrit on extraction recovery from VAMS tips 
[20–23].
A recent study shows that tacrolimus can be reliably 
measured in VAMS throughout the complete dose interval 
of tacrolimus in renal transplant patients when compar-
ing fingerprick VAMS (Mitra®) results to paired venous 
WB samples [24]. However, in the latter study, the sample 
quality of VAMS was not discussed. In addition, there are 
no studies that directly compare the performance of finger-
prick VAMS to fingerprick DBS for immunosuppressants. 
Only one study exists where fingerprick VAMS (Mitra®) 
samples and fingerprick glass capillary tube samples 
(Drummond Aqua-Cap®) were compared to venous WB 
samples for the drug radiprodil showing an underestima-
tion of radiprodil exposure in VAMS (but not for capillary 
tube sampling) compared to venous WB [25].
In the current study, we compared both a novel VAMS 
sampling device (Mitra®) and conventional DBS sampling 
to venous WB sampling with regard to interchangeability 
of analytical results and sample quality.
Materials and methods
Training of phlebotomists
For the DBS sampling, all phlebotomists were trained at the time DBS 
sampling was introduced (2016). At that time, the training consisted 
of a 15-min lecture explaining the sampling procedure, including 
common pitfalls and how to avoid them.
Because VAMS sampling was new in our hospital, the same 
phlebotomists were trained specifically for the VAMS sampling pro-
cedure. Although individual training of phlebotomists, including 
performing the sampling method themselves, is preferred, this was 
not feasible for one study coordinator for approximately 75 phle-
botomists [26, 27]. Therefore, similar to the previous DBS validation 
studies performed in our hospital, all phlebotomists were trained in 
a 15-min lecture explaining the sampling procedure, including com-
mon pitfalls and how to avoid them based on information provided 
by literature and the manufacturer of the VAMS tips (Neoteryx, Tor-
rance, CA, USA) [2, 13, 19, 28]. An analysis was performed to evaluate 
if a learning effect over time could be observed on VAMS sampling. 
The percentage of sufficient quality tips for the first half of the sam-
ples was compared to the percentage of sufficient quality tips for the 
last half of the samples.
Ethical approval, patients, sample collection and sample 
quality
Patient samples were collected from tacrolimus-using adult kidney 
transplant patients during routine visits to the University Medical 
Center Groningen (UMCG, the Netherlands) for nephrologist con-
sultation and TDM. Because of the nature of this study, the need to 
provide written informed consent by the patients was waived by the 
Ethics Committee of the UMCG (Metc 2011.394). This research was 
conducted in accordance with the Declaration of Helsinki and the 
EMA guidelines for good clinical practice E6(R2) [29]. All matched 
samples were obtained within 10  min of each other by the same 
phlebotomist following written instructions available at the time of 
sampling. First, the WB sample was obtained. Afterwards, a finger-
pick was performed, and a DBS sample was obtained by letting two 
drops of blood fall freely on a Whatmann DMPK-C cards (GE Health-
care, Chicago, IL, USA) following a previously described method [27]. 
From the same fingerpick, two 20-μL VAMS tips (Mitra®, Neoteryx) 
were filled according to the manufacturer’s instructions. Because the 
WB samples were part of routine care, they were analyzed within a 
day. After receiving the DBS and VAMS samples, they were inspected 
independently by two experienced lab technicians for quality, based 
on predefined criteria described earlier [15, 27, 30, 31]. If the judgment 
of the technicians differed, consensus was obtained by discussing 
each other’s judgment. The DBS and VAMS samples were dried for 
at least 24 h at room temperature and packed in sealed plastic bags 
with a desiccant. The samples were stored at −20 °C until analysis 
was performed. Stability of tacrolimus in DBS samples was validated 
for 29 weeks and in VAMS samples for 50 days at −20 °C, so analysis 
occurred within these timeframes, respectively [23, 32, 33].
Equipment and procedures
Hematocrit of the WB samples was measured using a XN10/
XN20 hematology analyzer (Sysmex, Kobe, Japan).
Tacrolimus concentrations were analyzed in EDTA anti-coagu-
lated WB samples using a validated analysis method on a Thermo 
Fisher Scientific triple quadrupole Quantiva MS/MS system with 
a Thermo Fisher Scientific Vanquish UPLC system (Waltham, MA, 
USA) [34]. Tacrolimus DBS samples were analyzed using a validated 
method on the aforementioned Thermo Fisher Scientific LC-MS/MS 
system [32, 33, 35]. The VAMS samples were analyzed for tacrolimus 
using a validated method on the aforementioned Thermo Fisher Sci-
entific LC-MS/MS system [23]. The main difference between VAMS 
and DBS extraction, besides the need to manually punch the DBS 
samples, is the two-step extraction for VAMS samples where first 
60:40  methanol:water is added to redissolve the red blood cells. 
Afterwards, methanol is added (step 2) to extract the analytes. For 
DBS, only one extraction solvent (80:20 methanol:water) is used [23, 
33]. For liquid WB samples, tacrolimus is extracted using only meth-
anol. Zinc sulfate is added during extraction for additional protein 
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precipitation. Additional information regarding the VAMS, DBS and 
WB analysis methods, such as information on calibrators, standards, 
imprecision, extraction procedure, internal standard addition and 
traceability can be found in Supplement 1.
Statistical analysis
Clinical validation was performed based on relevant guidelines by 
the CLSI, FDA, EMA and the recently published Guideline on Devel-
opment and Validation of Dried Blood Spot-Based Methods for Thera-
peutic Drug Monitoring [27, 36–38]. In short, method comparison was 
performed using the Passing-Bablok regression analysis [39]. The 
Bland-Altman analysis was used to calculate bias [40]. The limit of 
clinical acceptance was set a priori at 85%–115% around the ratio 
of matched WB-DBS and matched WB-VAMS samples for at least 
80% of the samples in accordance with earlier studies [13, 27]. These 
limits were chosen in a multidisciplinary team consisting of trans-
plantation nephrologists, pharmacists and analysts and were based 
on current trough concentration targets and the relevant concentra-
tion window for tacrolimus in kidney transplantation in combina-
tion with the aspects of the analytical method used for VAMS, DBS 
and WB [1, 13, 32–35]. The predictive performance of both the DBS 
and VAMS method was established using the method described by 
Sheiner and Beal [41]. In short, WB concentrations were predicted 
from both DBS and VAMS concentrations according to a previously 
described method [3, 13, 27]. The bias of the prediction is the median 
difference between the predicted and true concentration and is 
shown by the median prediction error (MPE) and the median per-
centage prediction error (MPPE). The imprecision is the variance of 
the predicted values which is measured by the root median squared 
prediction error (RMSE) and the median absolute percentage predic-
tion error (MAPE). The following equations were used:
 Median Prediction Error (MPE) median (Predicted WB WB)= −  (1)
 
Median Percentage Prediction Error (MPPE)
Predicted WB WBmedian  100%  
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(4)
In accordance with other studies, acceptable values for MPPE and 
MAPE were set at <15% and at least 67% of all samples should 
have an absolute prediction error of <20% [3, 6, 13, 42]. Statistical 
analysis was performed using Analyse-it® Method Validation Edi-
tion for Microsoft Excel version 4.18.6 (Analyse-it, Leeds, UK) and 
Microsoft Excel 2010 (Microsoft Inc., Redmond, WA, USA). Nor-
mality was tested using a Shapiro-Wilk test. All categorical data 
were expressed as percentages. Numeric data were expressed as 
mean ± standard deviation (SD) and range when normally distrib-




In total, 130  matched samples were obtained from 107 
adult kidney transplant patients between June 2018 and 
October 2018. For the VAMS samples, 42 (32.3%) of the 
samples were rejected because of insufficient quality, 
26  samples (20.0%) contained one sufficient quality tip 
and 62  samples (47.7%) contained two sufficient quality 
tips. Consensus between technicians was needed for eight 
(6.2%) of the VAMS samples. Three reasons for VAMS 
sample rejection were identified: (1) for 31 individual 
tips, the tip touched the cap of the sampling container 
caused by improper closing of the cap (Figure 1B); (2) for 
30 individual tips, the tip was oversaturated, caused by 
letting blood fall on the tip instead of dipping the tip in 
the blood (Figure 1C); (3) for 39 individual tips, the tip was 
undersaturated, caused by a too small amount of blood 
obtained from the fingerprick or not dipping the tip into 
the blood long enough (Figure 1D). When comparing the 
VAMS sample quality for the first half of the samples to the 
last half of the samples, no learning effect was observed 
(63.8% and 66.9% samples of sufficient quality, respec-
tively). For the DBS samples, eight samples (6.2%) were 
rejected because of insufficient quality, 23 samples (17.7%) 
contained one sufficient quality spot and 99 (76.2%) of the 
samples contained two sufficient quality spots.
Patients
In total, 88  matched samples from 72 unique patients 
were included in the method comparison analysis. Patient 
demographics are summarized in Table 1. The median 
concentrations of tacrolimus in WB, DBS and VAMS can 
be found in Table 2. Average hematocrit was 0.39 with a 
SD of 0.05 and a range of 0.25‒0.50. All tacrolimus concen-
trations were within the analytically validated range. All 
hematocrit values were within the analytically validated 
range.
Clinical validation of VAMS
The Passing-Bablok fit was y = 0.88x + 0.01 (95% CI slope, 
0.81‒0.97; 95% CI intercept, −0.47‒0.39) showing no sig-
nificant constant difference. A significant systematic dif-
ference of 12% lower tacrolimus concentration in VAMS 
compared to WB was observed (Figure 2). This systematic 
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difference was used to derive the following conversion 
formula: [tacrolimus WB concentration] = [tacrolimus 
VAMS concentration]/0.88. This conversion formula 
was used to recalculate all VAMS values, and these 
recalculated values were used in Bland-Altman analysis 
[27]. No significant bias was found in Bland-Altman anal-
ysis, with a mean WB/VAMS ratio of 1.00 (95% CI 0.98–
1.02) as shown in Figure 2. In total, 83.0% of the matched 
Figure 1: Different types of quality in 20 μL volumetric absorptive microsampling (VAMS) samples.
(A) Sufficient quality VAMS sample meeting all requirements. (B) Insufficient quality VAMS sample because the containers’ cap touched 
the tip, blood is visible on the inside of the cap. (C) Insufficient quality VAMS sample because of oversaturation, blood is visible on the tip 




  n  Median (range)
Age, years   72  58 (21‒78)
Sex   72  42 male (58.3%)
    30 female (41.7%)
Time since 
transplantation
  72  1 year, 7 months, 25 days 
(22 days‒16 years, 4 months)
Table 2: Median tacrolimus concentrations including IQR and 
range.
Concentration n Median [IQR] (range)
Tacrolimus in WB, μg/L 88 6.2 [4.8‒8.3] (3.0‒24.3)
Tacrolimus in DBS, μg/L 88 6.2 [4.8‒8.3] (2.8‒23.5)
Tacrolimus in VAMS, μg/L 88 6.2 [4.8‒8.2] (2.8‒17.9)
DBS, dried blood spot; IQR, interquartile range; VAMS, volumetric 
absorptive microsampling; WB, whole blood.
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samples are within the limits of clinical acceptance 
meeting the requirement of at least 80%. Because of the 
correction factor used, the bias estimation in the predic-
tive performance was small with an MPE of 0.00 μg/L and 
an MPPE of 0.00%. The predictive performance of impre-
cision as shown by the RMSE was small with a value of 
0.54 μg/L. The MAPE was within acceptable limits (<15%) 
with a value of 8.74%. The acceptance limit for MAPE 
(>67% of samples with a value <20%) was met with 82 out 
of 88 samples (93.2%) (Figure 3).
Clinical validation of DBS
The Passing-Bablok fit was y = 0.99x + 0.02 (95% CI slope, 
0.95‒1.04; 95% CI intercept, −0.26‒0.28) showing no 
significant systematic or constant difference between 
WB and DBS as shown in Figure 2. Bland-Altman analy-
sis showed no significant bias, with a mean WB/DBS 
ratio of 1.01 (95% CI 0.99–1.02) as shown in Figure 2. 
The 95% limits of agreement (LoA) are within the limits 
of clinical acceptance set at ±15%. In total, 96.6% of the 
matched samples are within the limits of clinical accept-
ance meeting the requirement of at least 80%. The bias 
estimation in the predictive performance was small 
with an MPE of 0.00 μg/L and an MPPE of −0.04%. The 
predictive performance of imprecision as shown by the 
RMSE was small with a value of 0.32 μg/L. The MAPE was 
within acceptable limits (<15%) with a value of 5.18%. 
The acceptance limit for MAPE (>67% of samples with a 



































































































































































Figure 2: Method comparison between whole blood (WB) tacrolimus levels, volumetric absorptive microsampling (VAMS) tacrolimus levels 
and dried blood spot (DBS) tacrolimus levels for 88 matched samples.
In the upper left panel, the bold red continuous line is the Passing-Bablok regression line y = 0.88x + 0.01 (95% CI slope, 0.81‒0.97; 95% 
CI intercept, −0.47‒0.39) for WB vs. VAMS. The dotted/dashed line is the 15% limit of clinical acceptance. In the upper right panel, the 
bold red continuous line is the Passing-Bablok regression line y = 0.99x + 0.02 (95% CI slope, 0.95‒1.04; 95% CI intercept, −0.26‒0.28) 
for WB vs. DBS. The dotted/dashed line is the 15% limit of clinical acceptance. The lower left panel shows the Bland-Altman analysis bias 
estimation based on recalculated values for VAMS using the formula [tacrolimus WB concentration] = [tacrolimus VAMS concentration]/0.88. 
Calculated bias is 1.00 (95% CI 0.98–1.02). The dotted/dashed line is the 15% limit of clinical acceptance. The dashed line is the 95% limits 
of agreement (LoA). The lower right panel shows the Bland-Altman analysis bias estimation for WB vs. DBS of 1.01 (95% CI 0.99–1.02). The 
dotted/dashed line is the 15% limit of clinical acceptance. The dashed line is the 95% LoA.
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Discussion
This study showed good agreement between tacrolimus 
VAMS and tacrolimus WB concentrations, and very good 
agreement between tacrolimus DBS and tacrolimus WB 
concentrations in kidney transplant patients over a rel-
evant range of trough concentrations. The predictive per-
formance of both the VAMS and DBS meet the predefined 
criterion. Both VAMS (after correction) and DBS meet the 
predefined limits of clinical acceptance and can be used 
in transplant patient care.
The conclusion that DBS performs better than VAMS 
was unexpected. We considered that this might be caused 
by the fact that DBS sampling has been in use for over 
3 years in our hospital, allowing quality of DBS sampling 
and DBS analysis to improve. In our previous validation 
studies, performed prior to DBS implementation in routine 
care, no limits of clinical acceptance were set [2, 33]. In 
order to get more insight into the performance during the 
early adoptive phase of DBS, we applied the limits of clini-
cal acceptance used in this study to the data of the previ-
ous studies and show that these limits would not be met 
(respectively 78.9% [n = 82/104] [2] and 80.0% [n = 70/85]) 
[33]. The fact that the performance of the DBS assay has 
improved over time could be attributed to improvements 
in DBS sampling and/or DBS analysis methods or even the 
WB analysis which is used as the gold standard.
During VAMS analytical validation, recovery of 
tacrolimus was stable across a wide hematocrit range 
(0.20–0.60  v/v) and concentration range (3.0 μg/L–40 
μg/L), with a maximum bias of −8.3% at extreme values for 
hematocrit and tacrolimus concentrations (respectively 
0.20 v/v and 40 μg/L) [23]. Therefore, it was unexpected 
that the VAMS method showed a significant systematic 
difference of 12% lower tacrolimus concentration in VAMS 
compared to WB samples.
Because of insufficient sample quality, only 62 dupli-
cate VAMS samples were available for analysis [27]. Method 
comparison using the mean value of the duplicate samples 
yielded a similar conversion formula for VAMS in Passing-
Bablok analysis and similar bias in Bland-Altman analysis 
(data not shown). It can thus be concluded that duplicate 
VAMS sample analysis has no positive effect on the quality 
of the analysis results and has no added benefit.
Other studies report both lower and higher concen-
trations in VAMS compared to WB for various drugs [20, 
25]. The study by Kita et al. reported an average of 14% 
higher AUC for tacrolimus in rat tail blood collected in 
VAMS compared to wet rat tail blood samples [43]. In the 
study by Vethe et al., who performed a clinical validation 
study for tacrolimus with paired WB and VAMS samples 
from two full 12-h PK curves of 27 adult renal transplant 
patients totaling 679 matched samples of which 105 were 
trough concentrations, no significant systematic differ-
ences are observed between WB and VAMS samples for 
tacrolimus across the entire concentration and hemato-
crit range [24]. We consider three possible explanations 
for the lower concentrations of tacrolimus in VAMS com-
pared to WB in our study. The first is the possible influ-
ence of the anticoagulant on the analytical results [27]. 
During method validation and sample analysis for this 
study, citrate anti-coagulated blood was used for the 
calibration and quality control (QC) samples for both the 
DBS and VAMS samples [23, 33]. The obtained patient 
VAMS and DBS samples consisted of capillary blood 
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Figure 3: Predictive performance of calculating whole blood 
(WB) tacrolimus concentrations from both volumetric absorptive 
microsampling (VAMS) samples and dried blood spot (DBS) samples.
The upper panel shows the percentage prediction error of predicted 
to measured tacrolimus volumetric absorptive microsampling 
(VAMS) concentrations with acceptable prediction error set 
at −20% and 20% after applying the formula [tacrolimus WB 
concentration] = [tacrolimus VAMS concentration]/0.88. The 
lower panel shows the percentage prediction error of predicted to 
measured tacrolimus dried blood spots (DBS) concentrations with 
acceptable prediction error set at −20% and 20%.
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samples were anti-coagulated with EDTA. Although this 
proves to have no influence on DBS analytical results, 
the absence of the citrate anticoagulant in patient 
samples might lower the VAMS extraction recovery. It is 
interesting to see Vethe et  al. describe the use of water 
as the first extraction solvent while other studies used 
organic extraction solvents (e.g. methanol or methanol/
water) [20, 21, 23, 24, 43]. The application of pure water 
as the first added extraction solvent might overcome the 
potential effects of anti-coagulants from the VAMS tips. 
However, Vethe et  al. did not specify the anticoagulant 
of the blood used during method validation and patient 
sample analysis [24]. The second reason might be the 
batch-to-batch differences in blood wicking volume of 
the Mitra® tips. However, we observed only a difference of 
3% lower blood wicking volume in the batch of VAMS tips 
used for patient sampling compared to the batch of VAMS 
tips used during method development and validation, 
according to the certificates of conformance. The third 
reason might be the influence of ‘invisible undersam-
pling’ of VAMS samples. Oversaturated VAMS tips will 
all be identified and excluded from analysis. Although 
obviously undersaturated VAMS tips (see Figure 1D) will 
be identified and excluded, this might not be the case 
for slightly undersaturared VAMS tips. According to the 
sampling instruction, the VAMS tip should remain in the 
drop of fingerprick blood for 2 s after the tip turns com-
pletely red to allow the complete filling of the inside of 
the tip [28]. When removed earlier, the tip might not be 
completely filled with blood, without the possibility of 
identifying this during sample inspection. To investigate 
this, we assumed that, for samples that passed QC where 
the values of the two duplicate VAMS tips differed >10% 
compared to the mean of both samples, this was caused 
by invisible undersaturation. We assumed that only the 
higher of these two values would represent a properly 
saturated tip. This was the case for 17/62 samples. When 
using only the highest values in the Passing-Bablok analy-
sis, we still found a 7% lower concentration of tacrolimus 
in VAMS compared to WB. Combined with the 3% lower 
blood wicking volume a difference of 4% lower tacrolimus 
concentration in VAMS compared to WB remains, which 
might be attributed to the earlier mentioned effect of the 
anticoagulant combined with the extraction method.
When using the aforementioned conversion formula 
to calculate VAMS tacrolimus concentrations, the results 
from this study are comparable to the results of the study 
by Vethe et  al. In their study, a limit of clinical accept-
ance of 20% was defined [24]. In total, 97.1% of the trough 
concentration samples (n = 105) was within this limit. If 
a limit for clinical acceptance of 20% was applied to our 
study, 94.3% of the VAMS samples would be within this 
limit.
The rejection rate of 32.3% for the VAMS samples was 
unexpected. Phlebotomists were trained using a similar 
training method that was used for the previous DBS clini-
cal validation studies performed in our hospital. In these 
previous studies, rejection rates of DBS samples were 
0.0%–4.8% [2, 13, 33]. Possible explanations for the high 
VAMS rejection rate can be as follows: (1) letting drops of 
blood fall on the VAMS tip instead of absorbing the blood, 
because phlebotomists might be used to the free-falling 
drop of blood in DBS sampling (Figure 1C); (2) not enough 
blood from a single fingerprick to obtain a VAMS sample 
after a DBS sample might explain undersaturation (Figure 
1D); (3) touching the blood sample by improper closing of 
the lids of the purple Mitra® cartridge (Figure 1B). In the 
study by Vethe et  al., no data were provided on sample 
quality of VAMS tips [24]. Although their study did not 
state how many phlebotomists obtained the samples 
or how they were trained, it is likely that only a limited 
number of study coordinators obtained the samples 
because it was a full-curve PK study. Involving only a few 
study coordinators whose training included practicing all 
steps of the sampling method can lead to up to 100% suf-
ficient quality samples [26]. In our hospital, a total of 75 
different phlebotomists could have performed the VAMS 
sampling. It can be concluded that training is of essence 
in order to ensure acceptable sample quality. Even expe-
rience of phlebotomists with other microsampling tech-
niques such as DBS seems to be of no guarantee for good 
quality VAMS samples.
Although meeting the predefined limits of clinical 
acceptance, at this moment VAMS results are inferior to 
DBS results, regarding agreement with WB results. In 
addition, introduction of VAMS sampling would likely 
not improve the amount of sufficient quality samples 
produced by patients at home. As a consequence, con-
ventional DBS home sampling by transplant patients is 
currently the preferred microsampling method in our hos-
pital for TDM of tacrolimus.
In future clinical validation studies, sample acquisi-
tion by only a limited number of well-trained personnel 
is key in obtaining high-quality samples. The training 
method itself might be subject to assessment and include 
a practical test before staff members are allowed to 
obtain samples. In addition, studies are needed where 
patients perform both DBS and VAMS sampling in order 
to assess the true difference in sample quality and 
patients’ sampling method preference. In such a study, 
the costs for both VAMS and DBS home sampling should 
also be assessed.
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